FLGT vs. CPRX
Compare and contrast key facts about Fulgent Genetics, Inc. (FLGT) and Catalyst Pharmaceuticals, Inc. (CPRX).
Scroll down to visually compare performance, riskiness, drawdowns, and other indicators and decide which better suits your portfolio: FLGT or CPRX.
Correlation
The correlation between FLGT and CPRX is 0.26, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.
Performance
FLGT vs. CPRX - Performance Comparison
Loading data...
Key characteristics
FLGT:
-0.21
CPRX:
1.19
FLGT:
0.04
CPRX:
1.95
FLGT:
1.00
CPRX:
1.22
FLGT:
-0.10
CPRX:
1.65
FLGT:
-0.39
CPRX:
6.46
FLGT:
22.38%
CPRX:
7.40%
FLGT:
46.32%
CPRX:
41.35%
FLGT:
-91.69%
CPRX:
-94.25%
FLGT:
-88.93%
CPRX:
-5.32%
Fundamentals
FLGT:
$619.53M
CPRX:
$2.97B
FLGT:
-$1.33
CPRX:
$1.57
FLGT:
1.32
CPRX:
0.00
FLGT:
2.12
CPRX:
5.56
FLGT:
0.55
CPRX:
3.65
FLGT:
$292.45M
CPRX:
$534.65M
FLGT:
$111.47M
CPRX:
$441.72M
FLGT:
-$47.19M
CPRX:
$250.28M
Returns By Period
In the year-to-date period, FLGT achieves a 10.18% return, which is significantly lower than CPRX's 16.77% return.
FLGT
10.18%
13.94%
17.56%
-7.96%
3.47%
N/A
CPRX
16.77%
8.21%
18.30%
47.79%
40.03%
19.87%
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Risk-Adjusted Performance
FLGT vs. CPRX — Risk-Adjusted Performance Rank
FLGT
CPRX
FLGT vs. CPRX - Risk-Adjusted Performance Comparison
This table presents a comparison of risk-adjusted performance metrics for Fulgent Genetics, Inc. (FLGT) and Catalyst Pharmaceuticals, Inc. (CPRX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Loading data...
Dividends
FLGT vs. CPRX - Dividend Comparison
Neither FLGT nor CPRX has paid dividends to shareholders.
Drawdowns
FLGT vs. CPRX - Drawdown Comparison
The maximum FLGT drawdown since its inception was -91.69%, roughly equal to the maximum CPRX drawdown of -94.25%. Use the drawdown chart below to compare losses from any high point for FLGT and CPRX. For additional features, visit the drawdowns tool.
Loading data...
Volatility
FLGT vs. CPRX - Volatility Comparison
Fulgent Genetics, Inc. (FLGT) has a higher volatility of 21.64% compared to Catalyst Pharmaceuticals, Inc. (CPRX) at 10.00%. This indicates that FLGT's price experiences larger fluctuations and is considered to be riskier than CPRX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading data...
Financials
FLGT vs. CPRX - Financials Comparison
This section allows you to compare key financial metrics between Fulgent Genetics, Inc. and Catalyst Pharmaceuticals, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
FLGT vs. CPRX - Profitability Comparison
FLGT - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Fulgent Genetics, Inc. reported a gross profit of 28.35M and revenue of 73.46M. Therefore, the gross margin over that period was 38.6%.
CPRX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a gross profit of 123.51M and revenue of 141.42M. Therefore, the gross margin over that period was 87.3%.
FLGT - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Fulgent Genetics, Inc. reported an operating income of -11.90M and revenue of 73.46M, resulting in an operating margin of -16.2%.
CPRX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported an operating income of 63.37M and revenue of 141.42M, resulting in an operating margin of 44.8%.
FLGT - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Fulgent Genetics, Inc. reported a net income of -11.53M and revenue of 73.46M, resulting in a net margin of -15.7%.
CPRX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, Catalyst Pharmaceuticals, Inc. reported a net income of 56.74M and revenue of 141.42M, resulting in a net margin of 40.1%.